GOLL JOHN 4

What Happened

• John Goll, SVP, Finance & CAO of Immunocore (IMCR), sold 698 shares in an open-market "sell-to-cover" transaction on Feb 18, 2026 at a weighted average price of $32.35, totaling $22,580.
• The Form 4 also reports activity on Feb 17, 2026: conversion/exercise of 1,351 derivative shares (reported at $0) and grant/award entries for 7,411 and 21,252 shares (reported at $0), reflecting RSU/derivative awards and related settlements.

Key Details

• Transaction dates/prices: Feb 17, 2026 (derivative exercise/conversion at $0; awards granted at $0); Feb 18, 2026 (sale of 698 shares at weighted avg $32.35; sale prices ranged $32.18–$32.72 per filing).
• Value of sale: $22,580 (698 × $32.35 weighted avg).
• Shares owned after the reported transactions: not specified in the excerpt of the filing provided.
• Notable footnotes: (F1) Ordinary shares may be represented by ADSs (1 ADS = 1 ordinary share); (F2) the 698-share sale was a sell-to-cover to satisfy income tax liabilities on RSU vesting; (F3) the $32.35 is a weighted average (range $32.18–$32.72); (F4–F7) describe RSU/option definitions and vesting schedules for the awards and option grants.
• Filing timeliness: Form 4 filed Feb 19, 2026 for transactions on Feb 17–18, 2026 — the filing appears timely.

Context

• The sell-to-cover was used to satisfy tax withholding on RSU vesting and is a routine administrative sale rather than a straightforward discretionary sale of remaining holdings.
• The filing shows derivative conversions/exercises and awards (RSUs/options) with vesting schedules noted in the footnotes; some shares related to those awards may vest over multiple future dates.
• This activity is informational for investors tracking insider holdings and compensation-related share movements; it does not, by itself, indicate a buy/sell signal about company prospects.